KRAS status is associated with metabolic parameters in metastatic colorectal cancer according to primary tumour location

Tabuso, M., Christian, M. ORCID: 0000-0002-1616-4179, Kimani, P., Gopalakrishnan, K. and Arasaradnam, R., 2020. KRAS status is associated with metabolic parameters in metastatic colorectal cancer according to primary tumour location. Pathology and Oncology Research. ISSN 1219-4956 (Forthcoming)

[img] Text
1332994_Christian.pdf - Post-print
Restricted to Repository staff only

Download (466kB)

Abstract

Background: Colorectal cancer (CRC) is characterized by complex interplay between macroenvironmental factors and tumor microenvironment, leading to variable outcomes in CRC patients. To date, there is still a need to identify macroenvironment/microenvironment factors that could define subgroup of patients that would benefit from specific anti-cancer treatment in order to improve patient selection for individualized targeted-based therapy.

Aims: Aim of this study was to evaluate associations between metabolic parameters and KRAS status in metastatic CRC (mCRC) according to a new tumour site classification.

Methods: Retrospective data were extracted from a total of 201 patients diagnosed with mCRC between 2012 and 2017 extracted from an established CRC database at our tertiary institute. Clinical-pathological data, including age, gender, BMI, hypertension, diabetes, pre-CRC diagnosis serum lipid levels and KRAS status were recorded. Categorical characteristics were compared using chi-squared test. Continuous characteristics were compared using Mann-Whitney U test. Log rank test was used to compare hazards for survival. In all comparisons, a two-sided P value < 0.05 was considered statistically significant.

Results: Out of 201 patients, 170 patients with complete serum lipid profile were included in the analysis. In recto-sigmoid cancers there was a statistically significant association between high cholesterol:high-density lipoprotein (chol:HDL) ratio and KRAS mutation (OR 2.69, 95% CI 1.1-6.4, p=0,02). In non recto-sigmoid cancers, high cholesterol was associated with KRAS WT (OR 0.39, CI 0.15-0.97, p=0.04). In 22 patients with KRAS mutated recto-sigmoid cancer stage IV at diagnosis normal chol:HDL ratio was associated with a trend to better survival (p=0.06).

Conclusions: High chol:HDL ratio was significantly associated with KRAS mutated metastatic recto-sigmoid cancers. A subgoup of mCRC patients with KRAS mutated recto-sigmoid cancer may benefit from optimal lipid lowering treatment.

Item Type: Journal article
Publication Title: Pathology and Oncology Research
Creators: Tabuso, M., Christian, M., Kimani, P., Gopalakrishnan, K. and Arasaradnam, R.
Publisher: Springer
Date: 11 June 2020
ISSN: 1219-4956
Identifiers:
NumberType
1332994Other
Divisions: Schools > School of Science and Technology
Record created by: Jonathan Gallacher
Date Added: 18 Jun 2020 16:27
Last Modified: 18 Jun 2020 16:27
URI: http://irep.ntu.ac.uk/id/eprint/40050

Actions (login required)

Edit View Edit View

Views

Views per month over past year

Downloads

Downloads per month over past year